Grey Market Semaglutide: Injection Errors

Researchers at the University of Connecticut School of Pharmacy asked 20 adults to prepare an injection of grey market semaglutide using nothing but instructions they could find online. The participants completed 15 of the 34 required steps correctly, a mean of 44%, and the team recorded errors that could result in incorrect dosing, needle sticks, or infections^[1]. The paper appeared in Public Health Reports on 1 August 2026. It puts a number on a question the grey market has never had to answer: not whether the vial contains real drug, but whether the person who bought it can use it.

What the researchers actually measured

The assessment ran from 1 September 2025 through 30 January 2026 and enrolled 20 adults aged 18 or over, 12 male and 8 female, with a mean age of 40 years and a standard deviation of 21 years. The sample combined University of Connecticut college students with older adults^[1]. Participants were handed semaglutide and diluent vials plus the supplies required, then left to look the process up online. That design mirrors the real situation the authors describe: the websites selling these products do not sell the supplies and do not provide guidance^[1].

The team broke the process into 34 steps and awarded one point for each step completed successfully. They also asked each participant to rate their own confidence on a scale from 1 (no confidence) to 5 (complete confidence), before and after the demonstration^[1].

Fewer than half the steps went right

Participants completed 15 of the 34 steps correctly, a mean of 44% with a standard deviation of 50%^[1]. The abstract does not publish a step-by-step error breakdown, but it groups the failures into three categories: errors that could result in incorrect dosing, in needle sticks, or in infections. Those three cover most of what goes wrong with an injectable. The wrong amount of drug enters the body, the person handling the sharp gets injured, or the product picks up contamination on the way in.

Confidence was low and stayed low. The mean self-rating was 2.3 (SD 0.7) before the demonstration and 1.9 (SD 1.0) after, a difference that did not reach statistical significance (P = .19)^[1]. Read plainly: people did not feel capable going in, and attempting the task did not move them much either way. The authors conclude that untrained adults without experience injecting medications could be at high risk of adverse events when they try to self-administer grey market semaglutide using only internet information^[1].

A prefilled pen and a vial are not the same object

Authorised semaglutide does not arrive as a task. Ozempic holds an EU-wide marketing authorisation, can only be obtained with a prescription, and is supplied as a solution for injection in prefilled pens with the dose steps set by the prescriber^[2]. The MHRA-authorised and FDA-approved presentations work the same way, and a pharmacist is available to demonstrate the device. The regulatory status of semaglutide is prescription-only in every market we track, including the United States and the United Kingdom.

Grey market products are a different physical object with a different set of demands on the buyer. A separate 2026 review from some of the same University of Connecticut group catalogued 33 compounded semaglutide and tirzepatide products sold online and found that only 18% reported a beyond-use date and only 28% reported preferred storage conditions^[3]. When the label will not tell a buyer when the product expires or how to keep it, the preparation errors measured in the Public Health Reports study are only one layer of the problem.

What this study does not show

This is 20 people at one American university, and the authors say directly that future studies should assess a larger and more diverse population and check whether the pattern holds for other products sold as peptides without a prescription^[1]. It measured performance during a single observed demonstration. It did not follow anyone home, did not count adverse events, and cannot tell you how often people using these products actually end up harmed. The standard deviation of 50% around a mean of 44% also signals a wide spread, so some participants did considerably better than the average and some considerably worse.

The framing is American too. The authors describe a legal loophole that lets consumers buy products sold as peptide semaglutide without a prescription^[1]. No equivalent route exists in the EU, the EEA or the UK, where semaglutide is a prescription-only medicine and unauthorised supply is an offence. That does not stop the products crossing borders, but it does change what the law says about them. Our Germany regulation page and Denmark regulation page set out the position in two of those markets.

Where this lands

Regulators have spent years warning about the product side of this market. The World Health Organization issued Medical Product Alert No. 2/2024 in June 2024 after falsified Ozempic was detected in supply chains in Brazil, the United Kingdom and the United States, cautioning that falsified product may result in ineffective treatment "due to incorrect dosage, contamination with harmful substances, or use of unknown or substituted ingredients"^[4]. The MHRA has told buyers in the UK that weight-loss medicines bought from fake pharmacy websites and social media sellers may contain toxins and other ingredients that could cause real harm, and that buying them this way is against the law^[5].

The Connecticut work adds the half that gets less attention. Even if a vial contained exactly what its label claimed, most people in this sample could not have prepared it correctly. That is a separate failure mode from counterfeiting, and no certificate of analysis addresses it. Purity testing describes a batch. It says nothing about the person holding the syringe, and the same gap applies to every injectable sold this way, including BPC-157 and tesamorelin.

If you are considering semaglutide, that conversation belongs with a clinician who can assess whether it is appropriate for you and who can show you how the device is meant to be used. Our semaglutide peptide page covers the trial evidence, the adverse-event profile, and the country-by-country legal position in full.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription-only medicine in every jurisdiction we cover. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.